Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10501)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
EIF4E
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Responsed Disease | Hereditary Leiomyomatosis | ICD-11: 2C90 | ||
Responsed Drug | Everolimus | Investigative | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Glutathione metabolism | hsa00480 | |||
mTOR signaling pathway | hsa04150 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model |
ACHN cells | Papillary renal cell carcinoma | Homo sapiens | CVCL_1067 |
Caki-1 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0234 | |
HEK293 cells | Normal | Homo sapiens | CVCL_0045 | |
Response regulation | Everolimus and RSL3/Erastin could synergistically inhibit the viability and induce ferroptosis in Renal cell carcinoma cells. Mechanistically, the inhibition of the mTOR-4EBP1 axis was found to be essential for the synergistic effects of Everolimus and RSL3/Erastin. Everolimus in combination with RSL3/Erastin is a promising therapeutic option for RCC treatment. | |||
Hereditary Leiomyomatosis [ICD-11: 2C90]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Eukaryotic translation initiation factor 4E (EIF4E) | Protein coding | ||
Responsed Drug | Everolimus | Investigative | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Glutathione metabolism | hsa00480 | |||
mTOR signaling pathway | hsa04150 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model |
ACHN cells | Papillary renal cell carcinoma | Homo sapiens | CVCL_1067 |
Caki-1 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0234 | |
HEK293 cells | Normal | Homo sapiens | CVCL_0045 | |
Response regulation | Everolimus and RSL3/Erastin could synergistically inhibit the viability and induce ferroptosis in Renal cell carcinoma cells. Mechanistically, the inhibition of the mTOR-4EBP1 axis was found to be essential for the synergistic effects of Everolimus and RSL3/Erastin. Everolimus in combination with RSL3/Erastin is a promising therapeutic option for RCC treatment. | |||
Everolimus
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | |||
Drug for Ferroptosis | Inducer | |||
Response Target | Unspecific Target | |||
Responsed Disease | Hereditary Leiomyomatosis | ICD-11: 2C90 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Glutathione metabolism | hsa00480 | |||
mTOR signaling pathway | hsa04150 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model |
ACHN cells | Papillary renal cell carcinoma | Homo sapiens | CVCL_1067 |
Caki-1 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0234 | |
HEK293 cells | Normal | Homo sapiens | CVCL_0045 | |
Response regulation | Everolimus and RSL3/Erastin could synergistically inhibit the viability and induce ferroptosis in Renal cell carcinoma cells. Mechanistically, the inhibition of the mTOR-4EBP1 axis was found to be essential for the synergistic effects of Everolimus and RSL3/Erastin. Everolimus in combination with RSL3/Erastin is a promising therapeutic option for RCC treatment. | |||